Preliminary reports on a therapeutical trial in multiple sclerosis

Area of Science:

• Neurology
• Immunology
• Pharmacology

Background:

• Multiple Sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
• Existing therapies aim to modulate the immune response, but challenges remain in managing disease progression and side effects.
• Azathioprine and corticosteroids are immunosuppressants with potential benefits and drawbacks in MS treatment.

Purpose of the Study:

• To evaluate the efficacy and safety of a combined therapeutic regimen of azathioprine and steroids in definite MS patients.
• To investigate the potential of this combination to mitigate adverse effects associated with immunosuppressive monotherapy.

Main Methods:

• A therapeutic trial involving 34 definite MS subjects with Relapsing-Remitting (RR), Relapsing-Progressive (RP), and Chronic-Progressive (CP) courses.
• An alternating treatment protocol: azathioprine (2 mg/Kg/day for 15 days) followed by triamcinolone (40 mg IM single dose for 15 days).
• Clinical assessment of treatment response across different MS subtypes.

Main Results:

• The azathioprine-steroid combination therapy demonstrated particular utility in patients with Relapsing-Progressive (RP) MS.
• The treatment also showed potential benefits for patients in the early stages of Chronic-Progressive (CP) MS.
• Observations suggested a possible balancing of azathioprine's adverse effects through concurrent steroid administration.

Conclusions:

• Combined azathioprine and steroid therapy is a promising treatment option for specific forms of Multiple Sclerosis.
• This regimen appears particularly effective for Relapsing-Progressive MS and may be beneficial in early Chronic-Progressive MS.
• Further research is warranted to confirm efficacy and optimize the use of this combination therapy in MS management.